<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2703257173
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PONIZEX 40MG VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PANTOPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        130.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MS Pharma " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MS Pharma 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC02 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ponizex&reg; contains the active substance pantoprazole (as sodium sesquihydrate).<br />pantoprazole is a selective &ldquo;proton pump inhibitor&rdquo;, a medicine which reduces the amount of acid produced in your stomach. It is used for<br />treating acid-related diseases of the stomach and intestine. This preparation is injected into a vein and will only be given to you if your doctor<br />thinks pantoprazole injections are more suitable for you at the moment than pantoprazole tablets. Tablets will replace your injections as soon as your<br />doctor sees fit.</p><p>Ponizex&reg; is used for treating<br />- Reflux oesophagitis. An inflammation of your oesophagus (the tube which connects your throat to your stomach) accompanied by the regurgitation<br />of stomach acid.<br />- Stomach and duodenal ulcers.<br />- Zollinger-Ellison-Syndrome and other conditions producing too much acid in the stomach.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Ponizex&reg;</strong><br />- if you are allergic to pantoprazole or any of the other ingredients of this medicine (listed in section 6)<br />- If you are allergic to medicines containing other proton pump inhibitors.</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor, pharmacist or nurse before you are given Pantoprazole<br />-People who use multiple daily doses of proton pump inhibitor medicines for a long period of time (a year or longer) may have an increased risk of<br />fractures of the hip, wrist or spine. Talk to your doctor about your risk of bone fracture if you use Pantoprazole.<br />-If you have low magnesium levels in your body. This problem can be serious. Low magnesium can happen in some people who use a proton pump<br />inhibitor medicine for at least 3 months. If low magnesium levels happen, it is usually after a year of treatment. You may or may not have symptoms<br />of low magnesium.<br />- If you have severe liver problems. Please tell your doctor if you ever had problems with your liver in the past. He will check your liver enzymes more<br />frequently. In the case of a rise of liver enzymes the treatment should be stopped.<br />- If you are taking a medicine containing atazanavir (for the treatment of HIV-infection) at the same time as pantoprazole, ask your doctor for specific<br />advice.<br />- If you have ever had a skin reaction after treatment with a medicine similar to Pantoprazole that reduces stomach acid.<br />- If you are due to have a specific blood test (Chromogranin A).</p><p>Tell your doctor immediately if you notice any of the following symptoms:<br />an unintentional loss of weight, repeated vomiting, difficulty in swallowing, vomiting blood, you look pale and feel weak (anemia), you notice blood in your stools, chest pain, stomach pain, severe and/or persistent diarrhea, as Pantoprazole has been associated with a small increase in infectious<br />diarrhea.</p><p>If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment<br />with Pantoprazole. Remember to also mention any other ill e_ects like pain in your joints.<br />Your doctor may decide that you need some tests to rule out malignant disease because pantoprazole also alleviates the symptoms of cancer and<br />could cause delay in diagnosing it. If your symptoms continue in spite of your treatment, further investigations will be considered.<br />Taking a proton pump inhibitor like Pantoprazole, especially over a period of more than one year, may slightly increase your risk of fracture in the hip,<br />wrist or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).</p><p><strong>Children and adolescents</strong><br />Pantoprazole is not recommended for use in children, as it has not been proven to work in children below 18 years of age.</p><p><strong>Other medicines and Ponizex&reg;</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Pantoprazole may influence the effectiveness<br />of other medicines, so tell your doctor if you are taking<br />- medicines such as ketoconazole, itraconazole and posaconazole (used to treat fungal infections) or erlotinib (used for certain types of cancer)<br />because Pantoprazole may stop these and other medicines from working properly<br />- Warfarin and phenprocoumon, which affect the thickening, or thinning of&nbsp; the blood. You may need further checks<br />- atazanavir and other medicines used to treat HIV-infection<br />- Methotrexate (used to treat rheumatoid arthritis, psoriasis, and cancer). If you are taking methotrexate your doctor may temporarily stop your Pantoprazole treatment because pantoprazole can increase levels of methotrexate in the blood<br />- Fluvoxamine (used to treat depression and other psychiatric diseases). If you are taking _uvoxamine your doctor may reduce the dose<br />- rifampicin (used to treat infections)<br />- St. John&rsquo;s Wort (Hypericum perforatum) (used to treat mild depression).</p><p><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before<br />taking this medicine.<br />There are no adequate data from the use of pantoprazole in pregnant women. Excretion into human milk has been reported. If you are pregnant,<br />or think you may be pregnant, or if you are breast-feeding, you should use this medicine only if your doctor considers the benefit for you greater than the potential risk for your unborn child or baby.</p><p><strong>Driving and using machines</strong><br />Pantoprazole has no or negligible influence on the ability to drive and use machines.<br />If you experience side effects like dizziness or disturbed vision, you should not drive or operate machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your nurse or your doctor will administer the daily dose to you as an injection into a vein over a period of 2 &ndash; 15 minutes.<br />The recommended dose is For gastric ulcers, duodenal ulcers and reflux oesophagitis:<br />One vial (40 mg Ponizex&reg;) a day.<br />For the long-term treatment of Zollinger-Ellison syndrome and other conditions in which too much stomach acid is produced: Two vials (80 mg<br />Ponizex&reg;) a day.<br />Your doctor may later adjust the dose, depending on the amount of stomach acid you produce. If you are prescribed more than two vials (80 mg) a day, the injections will be given in two equal doses. Your doctor may prescribe a temporary dose of more than four vials (160 mg) a day. If your stomach acid level needs to be controlled rapidly, a starting dose of 160 mg (four vials) should be enough to lower the amount of stomach acid sufficiently.</p><p><strong>Patients with liver problems</strong><br />If you suffer from severe liver problems, the daily injection should be only 20 mg (half a vial).<br />&nbsp;</p><p><strong>Use in children and adolescents</strong><br />These injections are not recommended for use in children and adolescents under 18 years.<br />&nbsp;</p><p><strong>If you use more Ponizex&reg; than you should</strong></p><p>These doses are carefully checked by your nurse or your doctor so an overdose is extremely unlikely. There are no known symptoms of overdose.<br />If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If you get any of the following side effects, tell your doctor immediately, or contact the casualty department at your nearest hospital</p><p><strong>Serious allergic reactions (frequency rare, may affect less than 1 in 1,000 people):</strong> swelling of the tongue and/or throat, difficulty in swallowing, hives<br />(nettle rash), difficulty in breathing, allergic facial swelling (Quincke&rsquo;s oedema / angioedema), severe dizziness with very fast heartbeat and heavy sweating Serious skin conditions (frequency not known, frequency cannot be estimated from the available data): blistering of the skin and rapid deterioration of your general condition, erosion (including slight bleeding) of eyes, nose, mouth/lips or genitals (Stevens-Johnson-Syndrome, Lyell-Syndrome, Erythema multiforme) and sensitivity to light Other serious conditions (frequency not known, frequency cannot be estimated from the available data): yellowing of the skin or whites of the eyes (severe damage to liver cells, jaundice) or fever, rash, and enlarged kidneys sometimes with painful urination and lower back pain (serious inflammation of the kidneys) possibly leading to kidney failure.</p><p><strong>Other side effects are Common (may affect less than 1 in 10 people) </strong>inflammation<strong>&nbsp;</strong>of the wall of the vein and blood clotting (thrombophlebitis) where the medicine is injected; benign polyps in the stomach</p><p><strong>Uncommon (may affect less than 1 in 100 people) </strong>headache; dizziness; diarrhoea; feeling sick, vomiting; bloating and flatulence (wind); constipation;<br />dry mouth; abdominal pain and discomfort; skin rash, exanthema, eruption; itching; feeling weak, exhausted or generally unwell; sleep disorders</p><p><strong>Rare (may affect less than 1 in 1,000 people)</strong> distortion or complete lack of the sense of taste; disturbances in vision such as blurred vision; hives; pain in the joints; muscle pains; weight changes; raised body temperature; high fever; swelling of the extremities (peripheral oedema); allergic reactions; depression; breast enlargement in males</p><p><strong>Very rare (may affect less than 1 in 10,000 people):</strong> Disorientation<br /><strong>Not known (frequency cannot be estimated from the available data):</strong> hallucination, confusion (especially in patients with a history of these symptoms); decreased sodium level in blood, feeling of tingling, prickling, pins and needles, burning sensation or numbness; low levels of potassium which can cause muscle weakness, twitching or abnormal heart rhythm; muscle spasm or cramps; low levels of calcium; rash, possibly with pain in the joints.</p><p>If you are on Pantoprazole for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can<br />be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. If you get any of these symptoms,</p><p>please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may<br />decide to perform regular blood tests to monitor your levels of magnesium.</p><p><strong>Side effects identified through blood tests Uncommon (may affect less&nbsp;than 1 in 100 people): </strong>an increase in liver enzymes</p><p><strong>Rare (may affect less than 1 in 1,000 people): </strong>an increase in bilirubin; increased fats in the blood, sharp drop in circulating granular white blood cells, associated with high fever<br /><strong>Very rare (may affect less than 1 in 10,000 people):</strong> a reduction in the number of blood platelets, which may cause you to bleed or bruise more than<br />normal; a reduction in the number of white blood cells, which may lead to more frequent infections, coexisting abnormal reduction in the number of<br />red and white blood cells, as well as platelets.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30 &deg;C.<br />Keep container in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is pantoprazole as pantoprazole sodium sesquihydrate.<br />Each vial contains 40 mg of pantoprazole (as pantoprazole sodium sesquihydrate).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pantoprazole is a white to almost white powder for solution for injection. It comes in a 10 ml clear glass vial closed with Bromobutyl Rubber stopper
20 mm Lyophilized containing 40 mg powder for solution for injection.

Pack size is 10 vials.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder:</p><p>MS Pharma Saudi,<br />Riyadh, Kingdome Saudi Arabia.<br />info-ksa@mspharma.com</p><p><br />Manufacturer by:<br />MS Pharma- Jordan for MS Pharma-Saudi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Jun-2020
SPM190290

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="direction: rtl;">يحتوي بونيزكس على المادة الفعالة بانتوبرازول (سيسكويهايدرات الصوديوم). بانتوبرازول هو مثبط اختياري لمضخة البروتون والذي يعمل بدوره على إنقاص كمية الحمض الذي يُفرز بواسطة المعدة.&nbsp;&nbsp; يُستخدم في علاج أمراض المعدة والأمعاء المرتبطة بزيادة حمض المعدة. يستخدم هذا الدواء عبر حقنه في الوريد، على أن يُعطى إليك فقط عندما يرى الطبيب أن حُقن بانتوبرازول هي الطريقة المناسبة لك في ذلك الوقت فضلاً عن تناولك الأقراص من نفس الدواء.&nbsp; سيتم استبدال الحقن بالأقراص عندما يرى الطبيب الفرصة المناسبة التي تسمح بذلك.</p><p style="direction: rtl;">يُستخدم بونيزكس في علاج</p><p style="direction: rtl;">التهاب المريء الارتجاعي. التهاب في المريء (الأنبوب الذي يصل الحلق بالمعدة) مصحوبا بارتجاع لحمض المعدة</p><p style="direction: rtl;">قرحة في المعدة أو الإثنا عشر</p><p style="direction: rtl;">متلازمة زولينجر - إليسون بالإضافة إلى حالات مرضية أخرى تتسبب في زيادة إفراز حمض المعدة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;"><strong>لا تستخدم بونيزكس</strong></p><p style="direction: rtl;">إذا كانت لديك حساسية مفرطة لمادة بانتوبرازول أو لأي مكونات أخرى في هذا الدواء (من المكونات المذكورة في الفقرة 6)</p><p style="direction: rtl;">إذا كنت تعاني من حساسية لأي دواء آخر يحتوي على مثبطات مضخة البروتون</p><p style="direction: rtl;"><strong>التحذيرات والاحتياطات</strong></p><p style="direction: rtl;">استشر الطبيب أو الصيدلي أو الممرضة قبل تناول هذا الدواء</p><p style="direction: rtl;">قد يتعرض الأشخاص الذين يتناولون جرعات يومية متعددة من الأدوية المثبطة لمضخة البروتون لفترة طويلة من الزمن (سنة أو أكثر) لخطر متزايد من الإصابة بكسور في الورك أو الرسغ أو العمود الفقري.&nbsp; يُنصح باستشارة الطبيب فيما يتعلق بالمخاطر المحتملة من الإصابة بالكسور إثر تناول هذا الدواء</p><p style="direction: rtl;">إذا كنت تعاني من نقص في مستوى الماغنيسيوم في الدم. حيث يُمكن أن تكون هذه المشكلة أمرا خطيرا. يمكن أن يحدث نقص في مستوى الماغنيسيوم في بعض الأفراد الذين يتناولون هذا الدواء لمدة لا تقل عن 3 أشهر. عادة ما يحدث نقص في مستوى الماغنيسيوم بعد مرور عام من العلاج بهذا الدواء. يمكن أن تُصاب بأعراض نقص الماغنيسيوم ويمكن أيضا ألا تعاني من أية أعراض</p><p style="direction: rtl;">إذا كنت تعاني من مشاكل حادة في الكبد. يجب إبلاغ الطبيب إذا كنت قد عانيت في السابق من مشاكل في الكبد. سيقوم الطبيب حينها بمتابعة نسب إنزيمات الكبد لديك باستمرار. يجب إيقاف تناول الدواء في حالة حدوث ارتفاع في مستويات الإنزيمات الكبدية</p><p style="direction: rtl;">إذا كنت تتناول دواء يحتوي على أتازانافير (يستخدم لعلاج عدوى فيروس نقص المناعة البشري) في نفس الوقت الذي تتناول فيه هذا الدواء، فيجب حينها استشارة الطبيب لكي يرشدك إلى الحل الأمثل في هذه الحالة&nbsp;</p><p style="direction: rtl;">إذا سبق وعانيت من أي رد فعل جلدي تحسسي عند تناولك دواء مشابه لبانتوبرازول في إنقاص مستوى الحمض المعدي</p><p style="direction: rtl;">إذا اضطررت بسبب ذلك لإجراء اختبار دم خاص كروموجرانين A</p><p style="direction: rtl;">يجب إبلاغ الطبيب على الفور إذا لاحظت أي من هذه الأعراض التالية: فقدان الوزن بصورة غير متعمدة، القيء المتكرر، صعوبة في البلع، قيء دموي، إذا كنت تبدو شاحبا و / أو تشعر بالضعف (فقر الدم)، أو إذا لاحظت وجود دم في البراز، ألم في الصدر، ألم في المعدة، إسهال حاد و / أو إسهال مستمر وذلك لأن دواء بانتوبرازول مرتبط بتسببه في حدوث زيادة بسيطة في نسبة الإصابة بالإسهال المُعدِي</p><p style="direction: rtl;">إذا عانيت من ظهور طفح جلدي خاصة في المناطق المعرضة للشمس، فيجب حينها إبلاغ الطبيب في أقرب وقت ممكن حيث أنه قد يطلب منك التوقف عن تناول هذا الدواء. تذكر أيضا أنه من الضروري إخبار الطبيب عن أي حالة مرضية تعاني منها مثل ألم في المفاصل</p><p style="direction: rtl;">قد يقرر الطبيب أنك بحاجة إلى إجراء مزيد من الفحوصات من أجل استبعاد أي مرض سرطاني وذلك لأن بانتوبرازول يخفف من حدة أعراض السرطان مما يمكن أن يتسبب في تأخير التشخيص.&nbsp; إذ استمر وجود الأعراض المرضية رغم العلاج بهذا الدواء فسيتم الأخذ بعين الاعتبار إجراء مزيد من الفحوصات</p><p style="direction: rtl;">إذا كنت تتناول أدوية مثبطة لمضخة البروتون مثل بانتوبرازول، خاصة على مدى أكثر من عام واحد، قد يزيد ذلك قليلاً من خطر الاصابة بكسور في الورك أو الرسغ أو العمود الفقري</p><p style="direction: rtl;">يجب إبلاغ الطبيب إذ كنت تعاني من هشاشة العظام أو إذا كنت تتناول دواء كورتيكوستيرويد (والذي يعمل بدوره على زيادة خطورة الإصابة بهشاشة العظام)</p><p style="direction: rtl;"><strong>الأطفال والمراهقين</strong></p><p style="direction: rtl;">لا ينصح باستخدام هذا الدواء مع الأطفال، حيث أنه لم يتم التأكد حتى الآن من مدى فاعلية الدواء في الأطفال الأصغر من 18 عامًا</p><p style="direction: rtl;"><strong>تناول أدوية أخرى مع بونيزكس</strong></p><p style="direction: rtl;">يجب عليك إخبار الطبيب أو الصيدليّ إذا كنت تتناول أدوية أو تناولت مؤخرًا بعض الأدوية أو تنوي تناول أي دواء آخر. يمكن أن يؤثر هذا الدواء على فاعلية بعض الأدوية الأخرى، لذلك يجب إبلاغ الطبيب إذا كنت تتناول</p><p style="direction: rtl;">أدوية مثل كيتوكونازول، إيتراكونازول، بوسوكونازول (يستخدمون في علاج العدوى الفطرية) أو إيرلوتينيب (يستخدم في علاج أنواع معينة من السرطان) وذلك لأن بانتوبرازول يُمكن أن يمنع هذه الأدوية وغيرها عن العمل بفاعلية وكفاءة</p><p style="direction: rtl;">وارفرين وفينوبروكيومن الذي يؤثر سيولة الدم. قد تحتاج أيضا للتحقق من المزيد من الأدوية مثل</p><p style="direction: rtl;">أتازانافير والأدوية الأخرى التي تستخدم لعلاج عدوى فيروس نقص المناعة البشري</p><p style="direction: rtl;">ميثوتريكسات (يستخدم في علاج التهاب المفاصل الروماتويدي والصدفية والسرطان). إذا كنت تتناول دواء ميزوتريكسات فقد يقوم الطبيب بإيقاف العلاج بدواء بانتوبرازول مؤقتا لأن بانتوبرازول يمكنه أن يزيد من مستويات دواء ميزوتريكسات في الدم</p><p style="direction: rtl;">فلوفوكزامين (يستخدم لعلاج الاكتئاب وبعض الأمراض النفسية الأخرى). إذا كنت تتناول أي دواء من فئة - فوكزامين فقد يقوم الطبيب بتقليل جرعة الدواء</p><p style="direction: rtl;">ريفامباسين (المستخدم في علاج العدوى)</p><p style="direction: rtl;">نبتة سانت جونز (نبتة العرن المثقوب) (تستخدم كمستخلص عشبي لعلاج حالات الاكتئاب البسيطة)</p><p style="direction: rtl;"><strong>:تأثير الدواء على الحمل والرضاعة الطبيعية والخصوبة</strong></p><p style="direction: rtl;">يجب استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء في حالة السيدات الحوامل أو السيدات اللاتي تقمن بالرضاعة الطبيعية أو في حالات الاعتقاد بالحمل أو التخطيط لحدوث الحمل</p><p style="direction: rtl;">لا توجد بيانات كافية حول استخدام هذا الدواء في السيدات الحوامل. تم الإبلاغ عن إفراز هذا الدواء في لبن الأم. يجب عدم استخدام هذا الدواء في حالة السيدات الحوامل أو السيدات اللاتي تقمن بالرضاعة الطبيعية أو في حالات الاعتقاد بالحمل إلا إذا رأي الطبيب أن الفائدة العائدة عليك تفوق المخاطر المحتمل حدوثها في الطفل أو الجنين</p><p style="direction: rtl;"><strong>القيادة واستخدام الآلات</strong></p><p style="direction: rtl;">لا يؤثر الدواء مُطلقا ولا حتى بصورة طفيفة في القدرة على القيادة واستخدام الآلات</p><p style="direction: rtl;">يجب تجنب القيادة أو استخدام الآلات إذا عانيت من أعراض جانبية مثل الدوار أو تشوش الرؤية عند تناولك هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سيقوم الطبيب أو الممرضة بإعطائك جرعتك اليومية من الدواء في صورة حقنة وريدية في مدة زمنية تتراوح بين 2 إلى 15 دقيقة</p><p>الجرعة الموصى بها هي</p><p>:في حالات القرحة المعدية، قرحة الإثنا عشر، التهاب المريء الارتجاعي</p><p>عبوة واحدة (40 ملغم من بونيزكس) في اليوم</p><p>في العلاج طويل الأمد في الحالات المصابة بمتلازمة زولينجر - إليسون والحالات الأخرى التي ينتج عنها إفراز كثير جدا من حمض المعدة: عبوتان (80 ملغم من بونيزكس) في اليوم</p><p>يحتمل أن يعدّل الطبيب الجرعة فيما بعد، اعتمادا على كمية حمض المعدة التي تُنتجه.&nbsp; إذا وُصف لك تناول أكثر من عبوتين من الدواء (80 ملغم) في اليوم، فإنك ستأخذها على جرعتين منفصلتين بالتساوي.&nbsp;&nbsp; يمكن أيضا أن يصف الطبيب جرعة مؤقتة بتناول أكثر من 4 عبوات من الدواء (160 ملغم) في اليوم. إذا كنت في حاجة لإنقاص سريع في مستوى الحمض المعدي، فسيكون من الكافي تناول جرعة أوّلية مقدارها 160 ملغم (4 عبوات من الدواء) لإنقاص كمية الحمض المعدي بشكل كافي</p><p>الحالات التي تعاني من مشاكل في الكبد</p><p>إذا كنت تعاني من مشاكل حادة في الكبد، فإن الجرعة اليومية لك يجب ألا تزيد عن 20 ملغم (نصف عبوة)</p><p>استخدام الدواء مع الأطفال والمراهقين</p><p>لا ينصح باستخدام الدواء مع الأطفال والمراهقين الأصغر من 18 عاما</p><p>إذا تناولت جرعات من دواء بونيزكس أكثر من الموصى بها</p><p>يتم حساب الجرعات بدقة شديدة بواسطة الطبيب أو الممرضة لذلك فمن النادر التعرض لجرعة زائدة من هذا الدواء. لا توجد أعراض معروفة عند تناول جرعة زائدة منه</p><p>يرجى استشارة الطبيب أو الصيدلي أو الممرضة إذا كانت لديك أية أسئلة إضافية فيما يتعلق بتناول هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">مثل كافة الأدوية، فإن هذا الدواء يمكن أن يتسبب في ظهور بعض الأعراض جانبية، وعلى الرغم من ذلك فإنها لا تظهر على جميع المرضى</p><p style="direction: rtl;">إذا عانيت من أي من هذه الأعراض الجانبية الآتية، فيجب استشارة الطبيب على الفور أو التواصل مع قسم الطوارئ في أقرب مستشفى إليك</p><p style="direction: rtl;">&nbsp;<strong>رد فعل تحسسي خطير (معدل تكرار حدوثه نادر، يؤثر في أقل من 1 من بين 1,000 شخص):</strong> تورم في اللسان و / أو الحلق مع صعوبة في البلع وطفح جلدي ، صعوبة في التنفس، تورم تحسسي في الوجه (وذمة كوينك / وذمة وعائية) ، دوار شديد مع زيادة سرعة ضربات القلب والتعرّق بغزارة</p><p style="direction: rtl;"><strong>حالات مرضية خطيرة في الجلد (معدل تكرار حدوثها غير معروف، لا يمكن تحديد نسبة تكرارها من البيانات المتاحة):</strong> فقاعات / بثور على الجلد مع تفاقم سريع للحالة الصحية العامة، تآكل في أنسجة (بما في ذلك النزيف البسيط) العين والأذن والفم / الشفاه أو الأعضاء الجنسية، (متلازمة ستيفن - جونسون، متلازمة لايل، المرض الحُمامي متعدد الأشكال / احمرار بعض أجزاء الجسم) والحساسية للضوء</p><p style="direction: rtl;"><strong>بعض الحالات المرضية الخطيرة الأخرى (معدل تكرار حدوثها غير معروف، لا يمكن تحديد نسبة تكرارها من البيانات المتاحة)</strong></p><p style="direction: rtl;">اصفرار الجلد وبياض العينين (تلف شديد في خلايا الكبد، يرقان) أو ارتفاع في درجة الحرارة، طفح جلدي، تضخم الكليتين وأحيانا مع ألم عند التبول وألم في أسفل الظهر (التهاب خطير في الكلية) ويمكن أن يؤدي إلى الاصابة بفشل كلوي</p><p style="direction: rtl;"><strong>أعراض جانبية أخرى مألوفة الحدوث (يمكن أن تؤثر في أقل من 1 من بين 10 أشخاص):</strong> التهاب في جدار الأوردة وحدوث تجلط في الدم (التهاب الوريد التخثري) في موضع حقن الدواء؛ أو تكون سدائل حميدة في المعدة</p><p style="direction: rtl;"><strong>أعراض جانبية غير مألوفة (يمكن أن تؤثر في أقل من 1 من بين 100 شخص):</strong> صداع، دوار، إسهال، الشعور بالتعب، القيء، الانتفاخ وكثرة الغازات، إمساك، جفاف الفم، ألم في البطن وعدم الشعور بالارتياح في البطن، طفح جلدي، طفح ظاهر، طفح مع تكون فقاعات وبثور على الجلد، الحكّة، الشعور بالضعف أو الإنهاك أو الاحساس العام بالتعب بالإضافة إلى مشاكل في النوم</p><p style="direction: rtl;"><strong>أعراض جانبية نادرة (يمكن أن تؤثر في أقل من 1 من بين 1000 شخص):</strong> اختلال في حاسة التذوق أو فقدان كلي لحاسة التذوق، مشاكل في الرؤية مثل تشوش الرؤية، طفح جلدي، ألم في المفاصل، ألم في العضلات، تغيرات في الوزن، ارتفاع في درجة الحرارة، حُمى مرتفعة، تورم الأطراف (وذمة طرفية)، رد فعل تحسسي، اكتئاب، تضخم الثدي في الرجال</p><p style="direction: rtl;"><strong>أعراض جانبية نادرة جدا (تؤثر في أقل من 1 من بين 10,000 شخص):</strong> اضطراب في التركيز (توهان)</p><p style="direction: rtl;"><strong>أعراض جانبية غير محدّدة (لا يمكن تحديد نسبة التكرر من البيانات المتاحة):</strong> هلوسة، ارتباك ذهني (خاصة في المرضى الذين يعانون من تاريخ مرضي للإصابة بأي من هذه الأعراض)، نقص في مستوى الصوديوم في الدم، الشعور بالوخز والتنميل والدبابيس والإبر، الشعور بالحرقان أو التنميل، نقص في مستوى البوتاسيوم في الدم والذي قد يتسبب في ضعف العضلات أو الارتعاش العضلي أو اختلال في نظم ضربات القلب، تشنج عضلي أو تقلصات، نقص مستوى الكالسيوم، طفح جلدي ويحتمل وجود ألم في المفاصل</p><p style="direction: rtl;">إذا كنت تتناول بانتوبرازول لمدة تزيد عن 3 أشهر فمن المحتمل حدوث انخفاض في نسبة الماغنيسيوم في الدم.&nbsp; يمكن أن يتسبب نقص مستوى الماغنيسيوم في الشعور بالإجهاد وتقلص عضلي غير إرادي وتشتت في التركيز ونوبات صرعية ودوار وزيادة في معدل ضربات القلب. يجب إبلاغ الطبيب على الفور إّذا لاحظت إصابتك بأي من هذه الأعراض. يمكن أن يؤدي نقص مستويات الماغنيسيوم في الدم إلى نقص البوتاسيوم أو الكالسيوم في الدم.&nbsp; يحتمل أن يقرر الطبيب إجراء اختبار دم بصورة منتظمة من أجل متابعة مستوى الماغنيسيوم</p><p style="direction: rtl;"><strong>الأعراض الجانبية غير المألوفة المتعرف عليها عبر فحوصات الدم (يمكن أن تؤثر في أقل من 1 من بين 100 شخص):</strong> زيادة في نسبة إنزيمات الكبد</p><p style="direction: rtl;"><strong>الأعراض الجانبية النادرة (يمكن أن تؤثر في أقل من 1 من بين 1000 شخص): </strong>زيادة في نسبة البليروبين، زيادة الدهون في الدم، نقص مفاجئ وحاد في خلايا الدم البيضاء المحببة السابحة في الدم، ارتفاع في درجة الحرارة</p><p style="direction: rtl;"><strong>الأعراض الجانبية النادرة جدا (تؤثر في أقل من 1 من بين 10,000 شخص):</strong> نقص في عدد الصفائح الدموية والذي قد يتسبب في حدوث نزيف أو تكون كدمات بمعدل أكثر من الطبيعي، بالإضافة إلى نقص في عدد كرات الدم البيضاء مما ينتج عنه تكرر الإصابة بالعدوى، نقص مشترك في كل من كريات الدم البيضاء والحمراء والصفائح الدموية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تحتفظ به &nbsp;في درجة حرارة أعلى من 30 درجة مئوية</p><p>&nbsp;احفظ الدواء في العبوة الخارجية من أجل حمايته من الضوء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">يحتوي بونيزكس على المادة الفعالة بانتوبرازول في صورة سيسكويهايدرات الصوديوم</p><p style="direction: rtl;">تحتوي كل عبوة من الدواء على 40 ملغم من المادة الفعالة بانتوبرازول ( سيسكويهايدرات الصوديوم )</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            بانتوبرازول هو مسحوق أبيض تقريبا ويستخدم مع المحاليل من أجل حقنه. يتوفر الدواء بداخل عبوة زجاجية بسعة 10 مل، مع سدادة مطاطية حجمها 20 ملم وتحتوي بداخلها على 40 ملغم من بودرة جاهزة للحل لأجل الحقن الوريدي. 
المجموعة هو 10 عبوات.

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إم إس فارما السعودية</p><p>الرياض ، المملكة العربية السعودية</p><p>info-ksa@mspharma.com</p><p>صنعت بواسطة</p><p>إم إس فارما &ndash; الأردن لصالح إم إس فارما &ndash; المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يناير - 2020
SPM190290  

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ponizex Powder for solution for intravenous injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Material name	Quantity
Used/ Vial 
Pantoprazole sodium sesquihydrate*	44.88 mg
Mannitol		140 mg
Sodium citrate dihydrate	5mg
Sodium Hydroxide	QS
Water for Injection**	QS to 2 ml
Total Volume: 	2 ml (Before Iyophilisation)

. *Each 22.44 of Pantoprazole sodium sesquihydrate is equivalent to 20 mg Pantoprazole
**Disappeared during the Iyophilisation process

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for intravenous injection.
White to almost white cake 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Reflux esophagitis.</p><p>- Gastric and duodenal ulcer.</p><p>- Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicine should be administered by a healthcare professional and under appropriate medical supervision.</p><p>Intravenous administration of Pantoprazole 40 mg Powder for Solution for Injection is recommended only if oral administration is not appropriate. Data are available on intravenous use for up to 7 days. Therefore, as soon as oral therapy is possible, treatment with Pantoprazole 40 mg Powder for Solution for Injection IV should be discontinued and 40 mg pantoprazole p.o. should be administered instead.</p><p>&nbsp;</p><p>Dosage</p><p><u>Gastric and duodenal ulcer, reflux esophagitis </u></p><p>The recommended intravenous dose is one vial of Pantoprazole 40 mg Powder for Solution for Injection (40 mg pantoprazole) per day.</p><p><u>Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions </u></p><p>For the long-term management of Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions patients should start their treatment with a daily dose of 80 mg Pantoprazole 40 mg Powder for Solution for Injection. Thereafter, the dose can be titrated up or down as needed using measurements of gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily. A temporary increase of the dose above 160 mg pantoprazole is possible but should not be applied longer than required for adequate acid control.</p><p>In case a rapid acid control is required, a starting dose of 2 x 80 mg Pantoprazole 40 mg Powder for Solution for Injection is sufficient to manage a decrease of acid output into the target range (&lt; 10 mEq/h) within one hour in the majority of patients.</p><p>&nbsp;</p><p><u>Hepatic Impairment </u></p><p>A daily dose of 20 mg pantoprazole (half a vial of 40 mg pantoprazole) should not be exceeded in patients with severe liver impairment.</p><p><u>Renal Impairment </u></p><p>No dose adjustment is necessary in patients with impaired renal function</p><p><u>Elderly </u></p><p>No dose adjustment is necessary in elderly patients.</p><p><u>Paediatric population </u></p><p>The safety and efficacy of Pantoprazole 40 mg powder for solution for injection in children aged under 18 years have not been established. Therefore, Pantoprazole 40 mg powder for solution for injection is not recommended for use in patients below 18 years of age.</p><p>&nbsp;</p><p>Method of administration</p><p>A ready-to-use solution is prepared in 10 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection.</p><p>The prepared solution may be administered directly or may be administered after mixing it with 100 ml sodium chloride 9 mg/ml (0.9 %) solution for injection or glucose monohydrate 55 mg/ml (5 %) solution for injection.</p><p>After preparation the solution must be used within 12 hours.</p><p>The medicinal product should be administered intravenously over 2 - 15 minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, substituted benzimidazoles, or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gastric malignancy</u></p><p>Symptomatic response to pantoprazole may mask the symptoms of gastric malignancy and may delay diagnosis. In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis, anaemia or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded.</p><p>Further investigation is to be considered if symptoms persist despite adequate treatment.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>In patients with severe liver impairment, the liver enzymes should be monitored during therapy. In the case of a rise of the liver enzymes, the treatment should be discontinued.</p><p>&nbsp;</p><p><u>Co-administration with HIV protease inhibitors</u></p><p>Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir, due to significant reduction in their bioavailability.</p><p>&nbsp;</p><p><u>Gastrointestinal infections caused by bacteria</u></p><p>Treatment with Pantoprazole 40 mg powder for solution for injection may lead to a slightly increased risk of gastrointestinal infections caused by bacteria such as Salmonella and Campylobacter or C. difficile.</p><p>Pantoprazole, like all proton pump inhibitors (PPIs), might be expected to increase the counts of bacteria normally present in the upper gastrointestinal tract. Treatment with Pantoprazole 40 mg Powder for Solution for Injection may lead to a slightly increased risk of gastrointestinal infections caused by bacteria such as <em>Salmonella and</em> <em>Campylobacter. </em></p><p>&nbsp;</p><p><u>Hypomagnesaemia</u></p><p>Severe hypomagnesaemia has been reported in patients treated with PPIs like pantoprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.</p><p>For patients expected to be on prolonged treatment or who take PPIs with digoxin or medicinal products that may cause hypomagnesaemia (e.g., diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p><u>Bone fractures</u></p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10-40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.</p><p>&nbsp;</p><p><u>Subacute cutaneous lupus erythematosus (SCLE)</u></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Pantoprazole 40 mg Powder for Solution for Injection. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p>&nbsp;</p><p><u>Interference with laboratory tests</u></p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumors. To avoid this interference, Pantoprazole 40 mg Powder for Solution for Injection treatment should be stopped for at least 5 days before CgA measurements. If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Medicinal products with pH dependent absorption pharmacokinetics</u></p><p>Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with the absorption of other medicinal products where gastric pH is an important determinant of oral bioavailability, e.g. some azole antifungals such as ketoconazole, itraconazole, posaconazole and other medicine such as erlotinib.</p><p>&nbsp;</p><p><u>HIV protease inhibitors</u></p><p>Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir due to significant reduction in their bioavailability.</p><p>If the combination of HIV protease inhibitors with a proton pump inhibitor is judged unavoidable, close clinical monitoring (e.g. virus load) is recommended. A pantoprazole dose of 20 mg per day should not be exceeded. Dosage of the HIV protease inhibitor may need to be adjusted.</p><p>&nbsp;</p><p><u>Coumarin anticoagulants (phenprocoumon or warfarin)</u></p><p>Co-administration of pantoprazole with warfarin or phenprocoumon did not affect the pharmacokinetics of warfarin, phenoprocoumon or INR. However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin or phenoprocoumon concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding, and even death. Patients treated with pantoprazole and warfarin or phenprocoumon may need to be monitored for increase in INR and prothrombin time.</p><p><u>Methotrexate</u></p><p>Concomitant use of high dose methotrexate (e.g. 300 mg) and proton-pump inhibitors has been reported to increase methotrexate levels in some patients. Therefore in settings where high-dose methotrexate is used, for example cancer and psoriasis, a temporary withdrawal of pantoprazole may need to be considered.</p><p><u>Other interactions studies</u></p><p>Pantoprazole is extensively metabolized in the liver via the cytochrome P450 enzyme system. The main metabolic pathway is demethylation by CYP2C19 and other metabolic pathways include oxidation by CYP3A4.</p><p>Interaction studies with medicinal products also metabolized with these pathways, like carbamazepine, diazepam, glibenclamide, nifedipine, and an oral contraceptive containing levonorgestrel and ethinyl oestradiol did not reveal clinically significant interactions.</p><p>An interaction of pantoprazole with other medicinal products or compounds, which are metabolized using the same enzyme system, cannot be excluded.</p><p>Results from a range of interaction studies demonstrate that pantoprazole does not affect the metabolism of active substances metabolised by CYP1A2 (such as caffeine, theophylline), CYP2C9 (such as piroxicam, diclofenac, naproxen), CYP2D6 (such as metoprolol), CYP2E1 (such as ethanol) or does not interfere with p-glycoprotein related absorption of digoxin.</p><p>There were no interactions with concomitantly administered antacids.</p><p>Interaction studies have also been performed by concomitantly administering pantoprazole with the respective antibiotics (clarithromycin, metronidazole, amoxicillin). No clinically relevant interactions were found.</p><p><em>Medicinal products that inhibit or induce CYP2C19</em></p><p>Inhibitors of CYP2C19 such as fluvoxamine could increase the systemic exposure of pantoprazole. A dose reduction may be considered for patients treated long-term with high doses of pantoprazole, or those with hepatic impairment.</p><p>Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin and St John&acute;s wort (Hypericum perforatum) may reduce the plasma concentrations of PPIs that are metabolized through these enzyme systems.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy</u></em><em> </em></p><p>A moderate amount of data on pregnant women indicate no malformative or feto/neonatal toxicity of pantoprazole.</p><p>Animal studies have shown reproductive toxicity.</p><p>As a precautionary measure, it is preferable to avoid the use of Pantoprazole during pregnancy.</p><p><em><u>Breast-feeding</u></em><em> </em></p><p>Animal studies have shown excretion of pantoprazole in breast milk. There is insufficient information on the excretion of pantoprazole in human milk but excretion into human milk has been reported. A risk to the newborns/infants cannot be excluded. Therefore, a decision on whether to discontinue breast-feeding or to discontinue/abstain from pantoprazole therapy should take into account the benefit of breast-feeding for the child, and the benefit of pantoprazole therapy for the woman.</p><p><u>Fertility </u></p><p>There was no evidence of impaired fertility following the administration of pantoprazole in animal studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantoprazole has no or negligible influence on the ability to drive and use machines.</p><p>Adverse drug reactions such as dizziness and visual disturbances may occur. If affected, patients should not drive or operate machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Approximately 5% of patients can be expected to experience adverse drug reactions (ADRs). The most commonly reported ADR is injection site thrombophlebitis. Diarrhea and headache, occurred in approximately 1% of patients.</p><p>The table below lists adverse reactions reported with pantoprazole, ranked under the following frequency classification:</p><p>Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>Table 1. Adverse reactions with pantoprazole</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Common</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Rare</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Very rare</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Agranulocytosis</p></td><td style="vertical-align:top"><p>Thrombocytopenia;</p><p>Leukopenia</p><p>Pancytopenia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity (including anaphylactic reactions and anaphylactic shock)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyperlipidemia as and lipid increases (triglycerides, cholesterol);</p><p>Weight changes</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyponatremia</p><p>Hypomagnesaemia</p><p>Hypocalcaemia in association with hypomagnesemia;</p><p>Hypokalemia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Sleep disorders</p></td><td style="vertical-align:top"><p>Depression (and all aggravations)</p></td><td style="vertical-align:top"><p>Disorientation (and all aggravations)</p></td><td style="vertical-align:top"><p>Hallucination;</p><p>Confusion (especially in pre-disposed patients, as well as the aggravation of these symptoms in case of pre-existence)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Headache;</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Taste disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Disturbances in vision / blurred vision</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Diarrhea;</p><p>Nausea / vomiting;</p><p>Abdominal distension and bloating;</p><p>Constipation;</p><p>Dry mouth;</p><p>Abdominal pain and discomfort</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Liver enzymes increased (transaminases, &gamma;-GT)</p></td><td style="vertical-align:top"><p>Bilirubin increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hepatocellular injury;</p><p>Jaundice;</p><p>Hepatocellular failure</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash / exanthema / eruption;</p><p>Pruritus</p></td><td style="vertical-align:top"><p>Urticaria;</p><p>Angioedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Stevens-Johnson syndrome;</p><p>Lyell syndrome; Erythema multiforme; Photosensitivity;</p><p>Subacute cutaneous lupus erythematosus</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Fracture of the hip, wrist or spine</p></td><td style="vertical-align:top"><p>Arthralgia;</p><p>Myalgia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Muscle spasm as a consequence of electrolyte disturbances</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Interstitial nephritis (with possible progression to renal failure)</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Gynecomastia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Injection site thrombophlebitis</p></td><td style="vertical-align:top"><p>Asthenia, fatigue and malaise</p></td><td style="vertical-align:top"><p>Body temperature increased;</p><p>Oedema peripheral</p></td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no known symptoms of overdose in man.</p><p>Systemic exposure with up to 240 mg administered intravenously over 2 minutes were well tolerated. As pantoprazole is extensively protein bound, it is not readily dialyzable.</p><p>In the case of an overdose with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for acid related disorders, Proton pump inhibitors, ATC code: A02BC02</p><p><u>Mechanism of action</u></p><p>Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific action on the proton pumps of the parietal cells.</p><p>Pantoprazole is converted to its active form in the acidic environment in the parietal cells where it inhibits the H<sup>+</sup>, K<sup>+</sup>-ATPase enzyme, i. e. the final stage in the production of hydrochloric acid in the stomach. The inhibition is dose-dependent and affects both basal and stimulated acid secretion. In most patients, freedom from symptoms is achieved within 2 weeks. As with other proton pump inhibitors and H2 receptor inhibitors, treatment with pantoprazole reduces acidity in the stomach and thereby increases gastrin in proportion to the reduction in acidity. The increase in gastrin is reversible. Since pantoprazole binds to the enzyme distal to the cell receptor level, it can inhibit hydrochloric acid secretion independently of stimulation by other substances (acetylcholine, histamine, gastrin). The effect is the same whether the product is given orally or intravenously.</p><p><strong>5.1 Pharmacodynamic Properties</strong></p><p>The fasting gastrin values increase under pantoprazole. On short-term use, in most cases they do not exceed the upper limit of normal. During long-term treatment, gastrin levels double in most cases. An excessive increase, however, occurs only in isolated cases. As a result, a mild to moderate increase in the number of specific endocrine (ECL) cells in the stomach is observed in a minority of cases during long-term treatment (simple to adenomatoid hyperplasia). However, according to the studies conducted so far, the formation of carcinoid precursors (atypical hyperplasia) or gastric carcinoids as were found in animal experiments (see section 5.3) have not been observed in humans.</p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumors.</p><p>Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p><p>An influence of a long-term treatment with pantoprazole exceeding one year cannot be completely ruled out on endocrine parameters of the thyroid according to results in animal studies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General pharmacokinetics</u></p><p>Pharmacokinetics do not vary after single or repeated administration. In the dose range of 10 to 80 mg, the plasma kinetics of pantoprazole are linear after both oral and intravenous administration.</p><p><u>Distribution</u></p><p>Pantoprazole&#39;s serum protein binding is about 98%. Volume of distribution is about 0.15 l/kg.</p><p><u>Biotransformation</u></p><p>The substance is almost exclusively metabolized in the liver. The main metabolic pathway is demethylation by CYP2C19 with subsequent sulphate conjugation, other metabolic pathways include oxidation by CYP3A4.</p><p><u>Elimination</u></p><p>Terminal half-life is about 1 hour and clearance is about 0.1 l/h/kg. There were a few cases of subjects with delayed elimination. Because of the specific binding of pantoprazole to the proton pumps of the parietal cell the elimination, half-life does not correlate with the much longer duration of action (inhibition of acid secretion).</p><p>Renal elimination represents the major route of excretion (about 80%) for the metabolites of pantoprazole, the rest is excreted with the faeces. The main metabolite in both the serum and urine is desmethylpantoprazole which is conjugated with sulphate. The half-life of the main metabolite (about 1.5 hours) is not much longer than that of pantoprazole.</p><p><u>Special populations</u></p><p><em>Poor metabolisers</em></p><p>Approximately 3% of the European population lack a functional CYP2C19 enzyme and are called poor metabolisers. In these individuals the metabolism of pantoprazole is probably mainly catalyzed by CYP3A4. After a single-dose administration of 40 mg pantoprazole, the mean area under the plasma concentration-time curve was approximately 6 times higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were increased by about 60%. These findings have no implications for the posology of pantoprazole.</p><p><em>Renal impairment</em></p><p>No dose reduction is recommended when pantoprazole is administered to patients with impaired renal function (incl. dialysis patients). As with healthy subjects, pantoprazole&#39;s half-life is short. Only very small amounts of pantoprazole are dialyzed. Although the main metabolite has a moderately delayed half-life (2 - 3 h), excretion is still rapid and thus accumulation does not occur.</p><p><em>Hepatic impairment</em></p><p>Although for patients with liver cirrhosis (classes A and B according to Child), the half-life values increased to between 7 and 9 h and the AUC values increased by a factor of 5 - 7, the maximum serum concentration only increased slightly by a factor of 1.5 compared with healthy subjects.</p><p><em>Elderly</em></p><p>A slight increase in AUC and C<sub>max</sub> in elderly volunteers compared with younger counterparts is also not clinically relevant.</p><p><em>Paediatric population</em></p><p>Following administration of single intravenous doses of 0.8 or 1.6 mg/kg pantoprazole to children aged 2 - 16 years there was no significant association between pantoprazole clearance and age or weight. AUC and volume of distribution were in accordance with data from adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard to humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.</p><p>In the two-year carcinogenicity studies in rats neuroendocrine neoplasms were found. In addition, squamous cell papillomas were found in the forestomach of rats. The mechanism leading to the formation of gastric carcinoids by substituted benzimidazoles has been carefully investigated and allows the conclusion that it is a secondary reaction to the massively elevated serum gastrin levels occurring in the rat during chronic high-dose treatment. In the two-year rodent studies an increased number of liver tumors was observed in rats and in female mice and was interpreted as being due to pantoprazole&#39;s high metabolic rate in the liver.</p><p>A slight increase of neoplastic changes of the thyroid was observed in the group of rats receiving the highest dose (200 mg/kg). The occurrence of these neoplasms is associated with the pantoprazole-induced changes in the breakdown of thyroxine in the rat liver. As the therapeutic dose in man is low, no harmful effects on the thyroid glands are expected.</p><p>In animal reproduction studies, signs of slight fetotoxicity were observed at doses above 5 mg/kg. Investigations revealed no evidence of impaired fertility or teratogenic effects.</p><p>Penetration of the placenta was investigated in the rat and was found to increase with advanced gestation. As a result, concentration of pantoprazole in the foetus is increased shortly before birth.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol, Sodium citrate dihydrate, Sodium Hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantoprazole 40 mg powder for solution for injection should not be prepared or mixed with solvents other than those stated. (sodium chloride 9 mg/ml (0.9%) solution for injection or glucose 50 mg/ml (5%) solution for injection.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Two years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Keep container in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear Tubular Glass Vials (10R)</p><p>Bromobutyl Rubber stopper 20 mm Lyophilized</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A ready-to-use solution is prepared by injecting 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection into the vial containing the powder. The appearance of the product after reconstitution is a colorless to faintly yellow solution. This solution may be administered directly or may be administered after mixing it with 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection or glucose monohydrate 55 mg/ml (5%) solution for injection. Glass or plastic containers should be used for dilution.</p><p>After reconstitution, or reconstitution and dilution, chemical and physical in use stability has been demonstrated for 12 hours at 30&deg;C.</p><p>From a microbiological point of view, the product should be used immediately.</p><p>Pantoprazole 40 mg powder for solution for injection should not be prepared or mixed with solvents other than those stated.</p><p>The medicine should be administered intravenously over 2-15 minutes.</p><p>The contents of the vial are for single use only. Any product that has remained in the container or the visual appearance of which has changed (e.g. if cloudiness or precipitation is observed) should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi  



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>